摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,6-diethyl-1,2,4,5-tetrazine | 13717-91-4

中文名称
——
中文别名
——
英文名称
3,6-diethyl-1,2,4,5-tetrazine
英文别名
3,6-diethyl-[1,2,4,5]tetrazine;diethyl-[1,2,4,5]tetrazine;Diaethyl-[1,2,4,5]tetrazin;3,6-Diaethyl-1,2,4,5-tetrazin;3,6-Diethyl-1,2,4,5-tetrazin;3,6-Diethyl-s-tetrazin
3,6-diethyl-1,2,4,5-tetrazine化学式
CAS
13717-91-4
化学式
C6H10N4
mdl
——
分子量
138.172
InChiKey
FJLNLVDWWLZFIP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    51.6
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933990090

SDS

SDS:85f4ebb8f58dbf059f5826c72cb4778d
查看

反应信息

  • 作为反应物:
    描述:
    3,6-diethyl-1,2,4,5-tetrazine氘代二甲亚砜重水 为溶剂, 反应 48.0h, 生成 3,5-diethyl-1H-pyrazol-4-amine
    参考文献:
    名称:
    调整异腈/四嗪的化学反应以加速脱保护并形成稳定的结合物。
    摘要:
    异氰基是生物正交反应的重要功能,因为它会与四嗪快速反应形成稳定的共轭物或从3-异氰丙基中释放出有效载荷。在这里,我们提供了对初始环加成之后的解离步骤的机械见解,并分析了结构修饰如何影响这些过程。这项研究的三个主要成果对于为生物正交应用设计此类研究组具有重要意义。首先,在3-异氰基丙基的C-2处的阴离子稳定取代基促进β-消除并加速脱保护。第二,具有庞大取代基的四嗪即使与伯异腈也能形成稳定的亚胺共轭物,否则它们会迅速水解。第三,消除步骤与水解成醛无关,而是可以直接从亚胺中间体发生。这些发现将允许调整四嗪和异腈反应物的结构,以用于生物正交连接和释放化学。
    DOI:
    10.1021/acs.joc.9b02522
  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 在 亚硝酸 作用下, 生成 3,6-diethyl-1,2,4,5-tetrazine
    参考文献:
    名称:
    Mueller; Herrdegen, Journal fur praktische Chemie (Leipzig 1954), 1921, vol. <2> 102, p. 132
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • BIO-ORTHOGONAL DRUG ACTIVATION
    申请人:KONINKLIJKE PHILIPS N.V.
    公开号:US20160106859A1
    公开(公告)日:2016-04-21
    The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.
    该发明涉及一种用于治疗学的原药激活方法,其中使用了表现出彼此生物正交反应性的非生物活性化学基团。该发明还涉及一种包含至少一种原药和至少一种激活剂的试剂盒,其中原药包含药物和第一个生物正交反应基团(触发器),而激活剂包含第二个生物正交反应基团。该发明还涉及在上述方法和试剂盒中使用的靶向治疗剂。该发明特别适用于抗体药物偶联物和双特异性及三特异性抗体衍生物。
  • TETRAZINE-CONTAINING COMPOUNDS AND SYNTHETIC METHODS THEREOF
    申请人:The Regents of the University of California
    公开号:US20160223559A1
    公开(公告)日:2016-08-04
    Described herein are tetrazine derivatives and efficient synthetic methods of synthesis thereof using elimination-Heck cascade reaction. Provided herein is the synthesis of conjugated tetrazines from the tetrazine derivatives. Also provided herein are methods of use of the conjugated tetrazines as fluorogenic probes for live-cell imaging.
    本文描述了四唑衍生物及利用消除-Heck级联反应的高效合成方法。本文提供了从四唑衍生物合成共轭四唑的方法。本文还提供了将共轭四唑用作活细胞成像的荧光探针的使用方法。
  • [EN] CHANNEL PROTEIN ACTIVATABLE LIPOSOMES<br/>[FR] LIPOSOMES ACTIVABLES PAR DES PROTÉINES DE CANAL
    申请人:TAGWORKS PHARMACEUTICALS B V
    公开号:WO2014081300A1
    公开(公告)日:2014-05-30
    Disclosed is a liposome, comprising a lipid bilayer enclosing a cavity, wherein the bilayer comprises a channel protein releasably linked to an eight-membered non-aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The liposomes are used in a kit comprising the liposome, the liposomal membrane of which comprises a channel protein linked to a Trigger, and an Activator for the Trigger, wherein the Trigger comprises the eight- membered non-aromatic cyclic alkenylene group, and the Activator comprises a diene.
    揭示了一种脂质体,包括包裹腔的脂质双层,其中双层包括与八元非芳香环烯链基(优选为环辛烯基,更优选为反式环辛烯基)可释放地连接的通道蛋白。这些脂质体用于一种套装,包括该脂质体,其脂质体膜包括连接到触发器的通道蛋白,以及用于触发器的激活剂,其中触发器包括八元非芳香环烯链基,而激活剂包括二烯。
  • [EN] CHEMICALLY CLEAVABLE GROUP<br/>[FR] GROUPE CLIVABLE PAR VOIE CHIMIQUE
    申请人:TAGWORKS PHARMACEUTICALS B V
    公开号:WO2014081303A1
    公开(公告)日:2014-05-30
    Disclosed is the use of the reactive components of the inverse electron-demand Diels Alder reaction for chemical masking and unmasking in vitro. This can be applied in complex chemical reactions and, particularly in the synthesis of biomolecules, e.g. on solid supports. The reactice components are a dienophile, particularly a trans-cyclooctene, and a diene, particularly a tetrazine.
    本文揭示了逆电子需求Diels-Alder反应的反应性组分用于体外化学掩蔽和解除掩蔽。这可以应用于复杂的化学反应中,特别是在生物分子合成中,例如在固相支持上。反应性组分包括双烯,特别是反式环辛二烯,和二烯,特别是四氮唑。
  • [EN] ACTIVATABLE LIPOSOMES<br/>[FR] LIPOSOME POUVANT ÊTRE ACTIF
    申请人:TAGWORKS PHARMACEUTICALS B V
    公开号:WO2014081299A1
    公开(公告)日:2014-05-30
    Disclosed are reactive liposome, comprising a lipid bilayer enclosing a cavity, wherein the bilayer comprises a linkage to an eight-membered non-aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The liposomes are use in a kit comprising the liposome linked, directly or indirectly, to a Trigger, and an Activator for the Trigger, wherein the Trigger comprises an eight-membered non-aromatic cyclic alkenylene group, and the Activator comprises a diene.
    揭示了一种反应性脂质体,包括一个脂质双层包裹的腔隙,其中该双层包括与一个含有八个成员的非芳香环烯基基团连接的连接,最好是环辛烯基团,更好是反式环辛烯基团。这些脂质体用于一种工具包,该工具包包括直接或间接地与一个触发器连接的脂质体,以及用于触发器的活化剂,其中触发器包括一个含有八个成员的非芳香环烯基基团,而活化剂包括一个二烯。
查看更多

同类化合物

酸四嗪 甲四嗪-氨基叔丁酯 四嗪-氨基叔丁酯 嘧啶并[4,5-e]-1,2,3,4-四嗪 二甲基-1,2,4,5-四嗪 二氯均四嗪 METHYLTETRAZINE-ACID,甲基四嗪-羧基 6-苯基-1,2,4,5-四嗪-3-胺 6-乙基-1,2,4,5-四嗪-3-胺 6-丁基氨基-3-(3,5-二甲基吡唑-1-基)四嗪 6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-胺 3,6-二苯基-1,2,4,5-四嗪 3,6-二氨基-1,2-二氢-1,2,4,5-四嗪盐酸盐 3,6-二-4-吡啶基-1,2,4,5-四嗪 3,6-二-2-吡啶基-1,2,4,5-四嗪 3,6-二(噻吩-2-基)-1,2,4,5-四嗪 3,6-二(3-吡啶基)-1,2,4,5-四氮杂苯 3,6-二(3,5-二甲基-1H-吡唑-1-基)-1,2,4,5-四嗪 1-[6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-基]-2-(丙-2-亚基)肼 1,2-二氢-1,2,4,5-四嗪-3,6-二酮 1,2,4,5]四嗪-3,6-二羧酸 1,2,4,5-四嗪-3-胺 1,2,4,5-四嗪-3,6-二羧酸二甲酯 1,2,4,5-四嗪 (9CI)-吡咯并[2,1-d]-1,2,3,5-四嗪 (6-肼基-1,2,4,5-四嗪-3-基)肼 3-(3,5-Dimethyl-1-pyrazolyl)-6-(2-trifluoroacetylhydrazino)-1,2,4,5-tetrazine 3-cyclohexyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 3-ethyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 6-pentyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 3-benzyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 3-methyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine N'-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-yl)propionohydrazide 3-(2-ethylidenehydrazinyl)-6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine (1,2,4,5-tetrazine-3,6-diyl)dimethanol 3-amino-6-chloro-1,2,4,5-tetrazine 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N-methyl-1,2,4,5-tetrazin-3-amine N-(tert-butyl)-6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-amine 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N-(prop-2-en-1-yl)-1,2,4,5-tetrazin-3-amine 3-(2-pyrimidyl)-6-(2-hydroxy)ethyl-1,2,4,5-tetrazine 3-isopropyl-6-phenyl-1,2,4,5-tetrazine 6-butylamino-3-chlorotetrazine 3,6-di(1H-pyrazol-4-yl)-1,2,4,5-tetrazine N-(1H-tetrazol-5-yl)-1,2,4,5-tetrazin-3-amine 3-(3,5-dimethylpyrazolyl)-6-[tris(hydroxylmethyl)aminomethane]-1,2,4,5-tetrazine 2-([1,2,4]triazolo[4,3-b][1,2,4,5]tetrazin-3-ylamino)-2-(hydroxymethyl)propane-1,3-diol 6-amino-1,2,4-triazolo<4,3-b><1,2,4,5>tetrazine N-phenethyl-[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazin-3-amine 2,5-dioxopyrrolidin-1-yl 2-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl)acetate furazano-1,2,3,4-tetrazine 1,3-dioxide